VSTM
Price:
$3.85
Market Cap:
$171.35M
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 20...[Read more]
Industry
Biotechnology
IPO Date
2012-01-27
Stock Exchange
NASDAQ
Ticker
VSTM
According to Verastem, Inc.’s latest financial reports and current stock price. The company's current ROE is -212.61%. This represents a change of 146.18% compared to the average of -86.36% of the last 4 quarters.
The mean historical ROE of Verastem, Inc. over the last ten years is -316.05%. The current -212.61% ROE has changed -32.73% with respect to the historical average. Over the past ten years (40 quarters), VSTM's ROE was at its highest in in the September 2020 quarter at 10.12%. The ROE was at its lowest in in the December 2019 quarter at -540.48%.
Average
-316.05%
Median
-76.37%
Minimum
-2358.18%
Maximum
-50.40%
Discovering the peaks and valleys of Verastem, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.95%
Maximum Annual ROE = -50.40%
Minimum Annual Increase = -97.51%
Minimum Annual ROE = -2358.18%
Year | ROE | Change |
---|---|---|
2023 | -152.28% | -2.28% |
2022 | -155.83% | 68.24% |
2021 | -92.62% | 57.65% |
2020 | -58.75% | -97.51% |
2019 | -2358.18% | 3.95% |
2018 | -58.27% | -50.42% |
2017 | -117.54% | 133.20% |
2016 | -50.40% | -10.74% |
2015 | -56.47% | -6.07% |
2014 | -60.12% | 71.37% |
The current ROE of Verastem, Inc. (VSTM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-133.58%
5-year avg
-563.53%
10-year avg
-316.05%
Verastem, Inc.’s ROE is greater than Viking Therapeutics, Inc. (-12.73%), less than Trevena, Inc. (210.71%), less than Karyopharm Therapeutics Inc. (58.62%), greater than AcelRx Pharmaceuticals, Inc. (-118.55%), greater than Infinity Pharmaceuticals, Inc. (-3433.02%),
Company | ROE | Market cap |
---|---|---|
-12.73% | $4.68B | |
210.71% | $1.55M | |
58.62% | $74.76M | |
-118.55% | $14.58M | |
-3433.02% | $726.09K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verastem, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Verastem, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Verastem, Inc.'s ROE?
How is the ROE calculated for Verastem, Inc. (VSTM)?
What is the highest ROE for Verastem, Inc. (VSTM)?
What is the 3-year average ROE for Verastem, Inc. (VSTM)?
What is the 5-year average ROE for Verastem, Inc. (VSTM)?
How does the current ROE for Verastem, Inc. (VSTM) compare to its historical average?